Study of ONO-8539 in Patients With Overactive Bladder

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to investigate efficacy, safety and tolerability of ONO-8539 in patients with overactive bladder.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ono Pharmaceutical Co. Ltd
• Treatments: Tolterodine Tartrate

Criteria

Inclusion Criteria:

• Patients with medical history of Overactive Bladder symptoms for > 6 months

Exclusion Criteria:

• Patients who have a history or presence of other significant diseases, which in the opinion of the investigator, might compromise the patient's safety or the evaluation of the study results